

1. Lisowska A, Makarewicz-Wujec M, Dworakowska AM, Kozłowska-Wojciechowska M. Adherence to guidelines for pharmacological treatment of young adults with myocardial infarction in Poland: Data from Polish Registry of Acute Coronary Syndromes (PL-ACS). *Journal of clinical pharmacy and therapeutics*. 2019;44(3):471-8.
2. Tada H, Kawashiri M-a, Nohara A, Inazu A, Mabuchi H, Yamagishi M. Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia. *European heart journal*. 2017;38(20):1573-9.
3. Sánchez-Hernández CD, Torres-Alarcón LA, González-Cortés A, Peón AN. Ischemia/Reperfusion Injury: Pathophysiology, Current Clinical Management, and Potential Preventive Approaches. *Mediators of Inflammation*. 2020;20(20):1-13.
4. Huber CA, Meyer MR, Steffel J, Blozik E, Reich O, Rosemann T. Post-myocardial infarction (MI) care: medication adherence for secondary prevention after MI in a large real-world population. *Clinical therapeutics*. 2019;41(1):107-17.
5. Moreau C, Bajolle F, Siguret V, Lasne D, Golmard J-L, Elie C, et al. Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. *Blood, The Journal of the American Society of Hematology*. 2012;119(3):861-7.
6. JAMIL SA. Safety of Dietary and Herbal Supplements. Iatrogenicity: Causes and Consequences of Iatrogenesis in Cardiovascular Medicine. RUTGERS university press medicine ebook; 2018.
7. Harter K, Levine M, Henderson SO. Anticoagulation drug therapy: a review. *West J Emerg Med*. 2015;16(1):11-7.
8. Arif KM, Rahman MA. A review of warfarin dosing and monitoring. *Faridpur Medical College Journal*. 2018;13(1):40-3.
9. Tripathi MM, Egawa S, Wirth AG, Tshikudi DM, Van Cott EM, Nadkarni SK. Clinical evaluation of whole blood prothrombin time (PT) and international normalized ratio (INR) using a Laser Speckle Rheology sensor. *Scientific Reports*. 2017;7(1):1-8.
10. Farhoudi M, Rad SF, Mahmoudi J, Sadigh-Eteghad S, Roozbeh M, Singh RJ, et al. Effect of Chronic Stress on Coagulation Parameters in Warfarin-Treated Male Rats. *Journal of Experimental and Clinical Neurosciences*. 2020;7(1):1-7.
11. Kingsley JD, Figueroa A. Acute and training effects of resistance exercise on heart rate variability. *Clinical physiology and functional imaging*. 2016;36(3):179-87.
12. KIRIŞ T, Vatanserver S, YAZICI S, Çelik A, VARIŞ E, Karaca M, et al. Prognostic value of Prothrombin time in patients with acute coronary syndrome undergoing percutaneous coronary intervention. *Koşuyolu Heart Journal*. 2018;21(2):98-107.
13. Eledo BO, Igwe R, Okamgba OC, Izah SC. Effect of Exercise on Some Haemostatic Parameters Among Students in a Tertiary Educational Institution in Nigeria. *American Journal of Health Research*. 2017;5(5):145-8.
14. El-Kader SMA, Al-Jiffri OH. Coagulation, fibrinolytic and cytokines parameters response to weight reduction in obese subjects. *EC Gastroenterology and Digestive System*. 2017;1(1):179-85.
15. Pratesi A, Baldasseroni S, Burgisser C, Orso F, Barucci R, Silverii MV, et al. Long-term functional outcomes after cardiac rehabilitation in older patients. Data from the Cardiac Rehabilitation in Advanced aGE: EXercise TRaining and Active follow-up (CR-AGE EXTRA) randomised study. *European journal of preventive cardiology*. 2019;26(14):1470-8.
16. Siltari A, Vapaatalo H. Vascular Calcification, Vitamin K and Warfarin Therapy – Possible or Plausible Connection? *Basic & Clinical Pharmacology & Toxicology*. 2018;122(1):19-24.
17. Alappan Harish R, Kaur G, Manzoor S, Navarrete J, O'Neill WC. Warfarin Accelerates Medial Arterial Calcification in Humans. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2020;40(5):1413-9.
18. Domazetovic V, Marcucci G, Iantomasi T, Brandi ML, Vincenzini MT. Oxidative stress in bone remodeling: role of antioxidants. *Clinical Cases in Mineral and Bone Metabolism*. 2017;14(2):209-216.
19. Bailey S, Karsenty G, Gundberg C, Vashishth D. Osteocalcin and osteopontin influence bone morphology and mechanical properties. *Annals of the New York Academy of Sciences*. 2017;1409(1):79-84.
20. Rashdan NA, Sim AM, Cui L, Phadwal K, Roberts FL, Carter R, et al. Osteocalcin regulates arterial calcification via altered Wnt signaling and glucose metabolism. *Journal of Bone and Mineral Research*. 2020;35(2):357-67.
21. Lin X, Patil S, Gao Y-G, Qian A. The bone extracellular matrix in bone formation and regeneration. *Frontiers in Pharmacology*. 2020;11(1):1-15.
22. Zhang YT, Tang ZY. Research progress of warfarin-associated vascular calcification and its possible therapy. *Journal of cardiovascular pharmacology*. 2014;63(1):76-82.
23. Abbasi T, Banaeifar A, Arshadi S, Kazemzadeh Y. Evaluation of the Interactive Effect of Warfarin Administration with Continuous and Interval Training on Levels of Cardiac MGP Protein and Renal Function Indexes in Rats of Myocardial Infarction Model: An Experimental Study. *JRUMS*. 2022; 21(2): 165-186. [Farsi]
24. Huang HK, Liu PPS, Hsu JY, Lin SM, Peng CCH, Wang JH, et al. Risk of osteoporosis in patients with atrial fibrillation using non-vitamin k antagonist oral anticoagulants or warfarin. *Journal of the American Heart Association*. 2020;9(2):1-10.

25. Singulani MP, Stringhetta-Garcia CT, Santos LF, Morais SRL, Louzada MJQ, Oliveira SHP, et al. Effects of strength training on osteogenic differentiation and bone strength in aging female Wistar rats. *Scientific reports*. 2017;7(42878):1-11.
26. Rostamizadeh M, Elmieh A, Rahmani Nia F. Effects of Aerobic and Resistance Exercises on Anthropometric Indices and Osteocalcin, Leptin, Adiponectin Levels in Overweight Men. *Journal of Arak University of Medical Sciences*. 2019;22(1):85-95.
27. Keikhosravi F, Daryanoosh F, Koushkie Jahromi M, Nemati J. High-Intensity Interval Training Effects with Genistein on Serum Osteocalcin and Bone Alkaline Phosphatase in Female Elderly Rats. *Journal of Nutrition, Fasting and Health*. 2021;9(2):125-30.
28. Abbasi T, Nazarali P, Hedayati M, Alizadeh R. The effect of eight weeks of high intensity interval training on osteopontin and some bone mineral indices in young women. *Journal of Physical Education and sport*. 2018;18 (1):532-5.
29. Mendonca S, Gupta D, Valsan A, Tewari R. Warfarin related acute kidney injury: A case report. *Indian journal of nephrology*. 2017;27(1):78-80.
30. Kimachi M, Furukawa TA, Kimachi K, Goto Y, Fukuma S, Fukuhara S. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. *Cochrane Database of Systematic Reviews*. 2017; 2 (11); 1-5.
31. Priyanka P, Zarbock A, Izawa J, Gleason TG, Renfurum RW, Kellum JA. The impact of acute kidney injury by serum creatinine or urine output criteria on major adverse kidney events in cardiac surgery patients. *The Journal of thoracic and cardiovascular surgery*. 2020; 162(1): 143-151.
32. Roklicer R, Lakicevic N, Stajer V, Trivic T, Bianco A, Mani D, et al. The effects of rapid weight loss on skeletal muscle in judo athletes. *Journal of translational medicine*. 2020;18 (1):1-7.
33. Ebert N, Shlipak MG. Cystatin C is ready for clinical use. *Current Opinion in Nephrology and Hypertension*. 2020;29(6):591-8.
34. Gharaibeh KA, Hamadah AM, El-Zoghby ZM, Lieske JC, Larson TS, Leung N. Cystatin C predicts renal recovery earlier than creatinine among patients with acute kidney injury. *Kidney international reports*. 2018;3(2):337-42.
35. Rimes-Stigare C, Ravn B, Awad A, Torlén K, Martling C-R, Bottai M, et al. Creatinine-and cystatin C-based incidence of chronic kidney disease and acute kidney disease in AKI survivors. *Critical care research and practice*. 2018;20 (1) :1-8.
36. Sun Y, Lu Q, Cheng B, Tao X. Prognostic value of cystatin C in patients with acute coronary syndrome: A systematic review and meta-analysis. *European Journal of Clinical Investigation*. 2021;51(3):1-11.
37. Calvo-Lobo C, Neyra-Bohorquez PP, Seco-Calvo J. Aerobic exercise effects in renal function and quality of life of patients with advanced chronic kidney disease. *Revista da Associação Médica Brasileira*. 2019;65(5):657-62.
38. Kotoku K, Yasuno T, Kawakami S, Fujimi K, Matsuda T, Nakashima S, et al. Effect of exercise intensity on renal blood flow in patients with chronic kidney disease stage 2. *Clinical and experimental nephrology*. 2019;23(5):621-8.
39. Hama T, Oikawa K, Ushijima A, Morita N, Matsukage T, Ikari Y-j, et al. Effect of cardiac rehabilitation on the renal function in chronic kidney disease-analysis using serum cystatin-C based glomerular filtration rate. *IJC heart & vasculature*. 2018;19 (1):27-33.
40. Nilsson CU, Strandberg K, Reinstrup P. Warfarin monitoring with viscoelastic haemostatic assays, thrombin generation, coagulation factors and correlations to Owren and Quick prothrombin time. *Scandinavian journal of clinical and laboratory investigation*. 2018;78(5):358-64.
41. Burn J, Pirmohamed M. Direct oral anticoagulants versus warfarin: is new always better than the old? *Open Heart*. 2018;5(1):1-5.
42. Shen G, Cui W, Zhang H, Zhou F, Huang W, Liu Q, et al. Warfarin traps human vitamin K epoxide reductase in an intermediate state during electron transfer. *Nature structural & molecular biology*. 2017;24(1):69-76.
43. Damkier P, Lassen D, Christensen MMH, Madsen KG, Hellfritzs M, Pottegård A. Interaction between warfarin and cannabis. *Basic & clinical pharmacology & toxicology*. 2019;124(1):28-31.
44. Jaffer IH, Weitz JI. Antithrombotic drugs. *Hematology*; 2018;11(1): 2168-88.
45. Boonyawat K, Wang L, Lazo-Langner A, Kovacs MJ, Yeo E, Schnurr T, et al. The effect of low-dose oral vitamin K supplementation on INR stability in patients receiving warfarin. *Thrombosis and haemostasis*. 2016;116(09):480-5.
46. Franchini M, Mengoli C, Cruciani M, Bonfanti C, Mannucci P. Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis: reply. *Journal of Thrombosis and Haemostasis*. 2015;13(6):1164-5.
47. Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH, et al. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. *New England Journal of Medicine*. 2017;376(17):1627-36.
48. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. *Circulation*. 2015;131(2):157-64.
49. Kura B, Szeiffova Bacova B, Kalocayova B, Sykora M, Slezak J. Oxidative stress-responsive microRNAs in heart injury. *International journal of molecular sciences*. 2020;21(1):1-19.
50. Bjørklund G, Svanberg E, Dadar M, Card DJ, Chirumbolo S, Harrington DJ, et al. The role of matrix Gla protein

- (MGP) in vascular calcification. *Current medicinal chemistry*. 2020;27(10):1647-60.
51. Poterucha TJ, Goldhaber SZ. Warfarin and vascular calcification. *The American journal of medicine*. 2016;129(6):635.e1-. e4.
 52. O'Neill WC, Adams AL. Breast arterial calcification in chronic kidney disease: absence of smooth muscle apoptosis and osteogenic transdifferentiation. *Kidney international*. 2014;85(3):668-76.
 53. Cozzolino M, Fusaro M, Ciceri P, Gasperoni L, Cianciolo G. The role of vitamin K in vascular calcification. *Advances in chronic kidney disease*. 2019;26(6):437-44.
 54. Krüger T, Oelenberg S, Kaesler N, Schurgers LJ, van de Sandt AM, Boor P, et al. Warfarin induces cardiovascular damage in mice. *Arteriosclerosis, thrombosis, and vascular biology*. 2013;33(11):2618-24.
 55. Millenaar D, Bachmann P, Böhm M, Custodis F, Schirmer SH. Effects of edoxaban and warfarin on vascular remodeling: Atherosclerotic plaque progression and collateral artery growth. *Vascular pharmacology*. 2020;127(1):1-7.
 56. Ware K, Qamri Z, Ozcan A, Satoskar AA, Nadasdy G, Rovin BH, et al. N-acetylcysteine ameliorates acute kidney injury but not glomerular hemorrhage in an animal model of warfarin-related nephropathy. *American Journal of physiology-Renal physiology*. 2013;304(12):F1421-F7.
 57. Wu W, Hu W, Han W-B, Liu Y-L, Tu Y, Yang H-M, et al. Inhibition of Akt/mTOR/p70S6K signaling activity with Huangkui capsule alleviates the early glomerular pathological changes in diabetic nephropathy. *Frontiers in pharmacology*. 2018;9(1):1-17.
 58. Wu C-S, Hu C-Y, Tsai H-F, Chyuan I-T, Chan C-J, Chang S-K, et al. Elevated serum level of growth arrest-specific protein 6 (Gas6) in systemic lupus erythematosus patients is associated with nephritis and cutaneous vasculitis. *Rheumatology international*. 2014;34(5):625-9.
 59. Di Maso V, Carraro M, Bevilacqua E, Bucconi S, Artero ML, Boscutti G. Warfarin-related nephropathy: possible role for the warfarin pharmacogenetic profile. *Clinical kidney journal*. 2014;7(6):605-8.
 60. Gabriel BM, Zierath JR. The limits of exercise physiology: from performance to health. *Cell metabolism*. 2017;25(5):1000-11.
 61. Tao L, Bei Y, Zhang H, Xiao J, Li X. Exercise for the heart: signaling pathways. *Oncotarget*. 2015;6(25): 20773–20784.
 62. Watson EL, Viana JL, Wimbury D, Martin N, Greening NJ, Barratt J, et al. The effect of resistance exercise on inflammatory and myogenic markers in patients with chronic kidney disease. *Frontiers in physiology*. 2017;8(5):1-14.
 63. Rouleau-Mailloux E, Shahabi P, Dumas S, Zada YF, Provost S, Hu J, et al. Impact of regular physical activity on weekly warfarin dose requirement. *Journal of thrombosis and thrombolysis*. 2016;41(2):328-35.
 64. Bernardo BC, Ooi JY, Weeks KL, Patterson NL, McMullen JR. Understanding key mechanisms of exercise-induced cardiac protection to mitigate disease: current knowledge and emerging concepts. *Physiological reviews*. 2018;98(1):419-75.
 65. Karlsen T, Aamot I-L, Haykowsky M, Rognum Ø. High intensity interval training for maximizing health outcomes. *Progress in cardiovascular diseases*. 2017;60(1):67-77.
 66. Wang Y, Xu D. Effects of aerobic exercise on lipids and lipoproteins. *Lipids in health and disease*. 2017;16(1):1-8.
 67. Connolly LJ, Bailey SJ, Krstrup P, Fulford J, Smetanka C, Jones AM. Effects of self-paced interval and continuous training on health markers in women. *European journal of applied physiology*. 2017;117(11):2281-93.
 68. Campbell WW, Kraus WE, Powell KE, Haskell WL, Janz KF, Jakicic JM, et al. High-intensity interval training for cardiometabolic disease prevention. *Medicine and science in sports and exercise*. 2019;51(6):1-13.
 69. Ribeiro F, Oliveira N, Silva G, Campos L, Miranda F, Teixeira M, et al. Exercise-based cardiac rehabilitation increases daily physical activity of patients following myocardial infarction: subanalysis of two randomised controlled trials. *Physiotherapy*. 2017;103(1):59-65.
 70. Piepoli MF, Corrà U, Adamopoulos S, Benzer W, Bjarnason-Wehrens B, Cupples M, et al. Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery: a policy statement from the cardiac rehabilitation section of the European Association for Cardiovascular Prevention & Rehabilitation. Endorsed by the Committee for Practice Guidelines of the European Society of Cardiology. *European journal of preventive cardiology*. 2014;21(6):664-81.
 71. Moholdt T, Madssen E, Rognum Ø, Aamot IL. The higher the better? Interval training intensity in coronary heart disease. *Journal of science and medicine in sport*. 2014;17(5):506-10.
 72. Connolly LJ, Nordsborg NB, Nyberg M, Weihe P, Krstrup P, Mohr M. Low-volume high-intensity swim training is superior to high-volume low-intensity training in relation to insulin sensitivity and glucose control in inactive middle-aged women. *European journal of applied physiology*. 2016;116(10):1889-97.
 73. Pei G, Tang Y, Tan L, Tan J, Ge L, Qin W. Aerobic exercise in adults with chronic kidney disease (CKD): a meta-analysis. *International urology and nephrology*. 2019;51(10):1787-95.
 74. Heiwe S, Jacobson SH. Exercise training in adults with CKD: a systematic review and meta-analysis. *American Journal of Kidney Diseases*. 2014;64(3):383-93.
 75. Wu F, Li Z, Cai M, Xi Y, Xu Z, Zhang Z, et al. Aerobic exercise alleviates oxidative stress-induced apoptosis in kidneys of myocardial infarction mice by inhibiting ALCAT1 and activating FNDC5/Irisin signaling pathway. *Free Radical Biology and Medicine*. 2020;158(1):171-80.
 76. Melo SFS, Barauna VG, Neves VJ, Fernandes T, da Silva Lara L, Mazzotti DR, et al. Exercise training restores the cardiac microRNA-1 and -214 levels regulating Ca²⁺ handling after myocardial infarction. *BMC Cardiovascular*

- Disorders. 2015;15(1):1-8.
77. Mahadevan V. Anatomy of the heart. *Surgery (Oxford)*. 2018;36(2):43-7.
 78. Planavila A, Fernández-Solà J, Villarroya F. Cardiokines as modulators of stress-induced cardiac disorders. *Advances in protein chemistry and structural biology*. 2017;108(1):227-56.
 79. Wu Y-S, Zhu B, Luo A-L, Yang L, Yang C. The role of cardiokines in heart diseases: beneficial or detrimental? *BioMed research international*. 2018;20(1):1-14.
 80. Liu M, Mao C, Li J, Han F, Yang P. Effects of the activin A–follistatin system on myocardial cell apoptosis through the endoplasmic reticulum stress pathway in heart failure. *International journal of molecular sciences*. 2017;18(2):374-94.
 81. El-Borm HT, Atallah MN. Protective effects of Zingiber officinale extract on myocardium and placenta against labetalol-induced histopathological, immune-histochemical, and ultrastructural alterations in pregnant rats. *The Journal of Basic and Applied Zoology*. 2021;82(1):1-15.
 82. Mehta PK, Wei J, Wenger NK. Ischemic heart disease in women: a focus on risk factors. *Trends in cardiovascular medicine*. 2015;25(2):140-51.
 83. Musher DM, Abers MS, Corrales-Medina VF. Acute infection and myocardial infarction. *New England Journal of Medicine*. 2019;380(2):171-6.
 84. Wang H, Paulsen MJ, Hironaka CE, Shin HS, Farry JM, Thakore AD, et al. Natural heart regeneration in a neonatal rat myocardial infarction model. *Cells*. 2020;9(1):229-249.
 85. Anderson JL, Morrow DA. Acute myocardial infarction. *New England Journal of Medicine*. 2017;376(21):2053-64.
 86. Sinha B, Ghosal S. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. *Diabetes research and clinical practice*. 2019;150(1):8-16.
 87. Silverstein D, Hopper K. *Small animal critical care medicine-E-Book: 2nd Edition, USA*, Elsevier Health Sciences, 2014, 1-508.
 88. Gupta P, Kanwal A, Putcha UK, Bulani Y, Sojitra B, Khatua TN, et al. Cardioprotective effect of ritonavir, an antiviral drug, in isoproterenol induced myocardial necrosis: a new therapeutic implication. *Journal of translational medicine*. 2013;11(1):1-6.
 89. Bai L, Kee HJ, Han X, Zhao T, Kee S-J, Jeong MH. Protocatechuic acid attenuates isoproterenol-induced cardiac hypertrophy via downregulation of ROCK1–Sp1–PKC γ axis. *Scientific reports*. 2021;11(1):1-16.
 90. Prasad EM, Mopuri R, Islam MS, Kodihela LD. Cardioprotective effect of Vitex negundo on isoproterenol-induced myocardial necrosis in wistar rats: a dual approach study. *Biomedicine & Pharmacotherapy*. 2017;85(1):601-10.
 91. Mitsuyama S, Takeshita D, Obata K, Zhang G-X, Takaki M. Left ventricular mechanical and energetic changes in long-term isoproterenol-induced hypertrophied hearts of SERCA2a transgenic rats. *Journal of molecular and cellular cardiology*. 2013;59(1):95-106.
 92. Li N, Zhou H, Ma Z-G, Zhu J-X, Liu C, Song P, et al. Geniposide alleviates isoproterenol-induced cardiac fibrosis partially via SIRT1 activation in vivo and in vitro. *Frontiers in pharmacology*. 2018; 9(1), 1-16.
 93. Panda S, Kar A, Ramamurthy V. Cardioprotective effect of vincristine on isoproterenol-induced myocardial necrosis in rats. *European journal of pharmacology*. 2014;723(1):451-8.
 94. Sithuraj S, Viswanadha VP. Berbamine protects the heart from isoproterenol induced myocardial infarction by modulating eNOS and iNOS expressions in rats. *Journal of Applied Biomedicine*. 2018;16(4):301-10.
 95. Oliveira JB, Soares AA, Sposito AC. Inflammatory response during myocardial infarction. *Advances in clinical chemistry*. 2018;84(1):39-79.
 96. Moser SC, van der Eerden BC. Osteocalcin A versatile bone-derived hormone. *Frontiers in endocrinology*. 2019;10(9):1-6.
 97. Mizokami A, Kawakubo-Yasukochi T, Hirata M. Osteocalcin and its endocrine functions. *Biochemical pharmacology*. 2017;132(1):1-8.
 98. Zoch ML, Clemens TL, Riddle RC. New insights into the biology of osteocalcin. *Bone*. 2016;82:42-9.
 99. Cavalier E, Lukas P, Bottani M, Aarsand A, Ceriotti F, Coşkun A, et al. European Biological Variation Study (Eu-BIVAS): within-and between-subject biological variation estimates of β -isomerized C-terminal telopeptide of type I collagen (β -CTX), N-terminal propeptide of type I collagen (PINP), osteocalcin, intact fibroblast growth factor 23 and uncarboxylated-unphosphorylated matrix-Gla protein—a cooperation between the EFLM Working Group on Biological Variation and the International Osteoporosis Foundation-International Federation of Clinical Chemistry Committee on Bone Metabolism. *Osteoporosis International*. 2020;31(8):1461-70.
 100. Fusaro M, Mereu MC, Aghi A, Iervasi G, Gallieni M. Vitamin K and bone. *Clinical Cases in Mineral and Bone Metabolism*. 2017;14(2):200-206.
 101. Li J, Zhang H, Yang C, Li Y, Dai Z. An overview of osteocalcin progress. *Journal of bone and mineral metabolism*. 2016;34(4):367-79.
 102. Mera P, Laue K, Ferron M, Confavreux C, Wei J, Galán-Diez M, et al. Osteocalcin signaling in myofibers is necessary and sufficient for optimum adaptation to exercise. *Cell metabolism*. 2016;23(6):1078-1092.
 103. Kanazawa I. Osteocalcin as a hormone regulating glucose metabolism. *World journal of diabetes*. 2015;6(18):1345-1354
 104. Mera P, Laue K, Wei J, Berger JM, Karsenty G. Osteocalcin is necessary and sufficient to maintain muscle mass in

- older mice. *Molecular metabolism*. 2016;5(10):1042-1047.
105. Lin X, Parker L, McLennan E, Zhang X, Hayes A, McConell G, et al. Recombinant uncarboxylated osteocalcin per se enhances mouse skeletal muscle glucose uptake in both extensor digitorum longus and soleus muscles. *Frontiers in endocrinology*. 2017;8(2):1-11.
 106. Tsuka S, Aonuma F, Higashi S, Ohsumi T, Nagano K, Mizokami A, et al. Promotion of insulin-induced glucose uptake in C2C12 myotubes by osteocalcin. *Biochemical and biophysical research communications*. 2015;459(3):437-42.
 107. Kim YS, Nam JS, Yeo DW, Kim KR, Suh SH, Ahn CW. The effects of aerobic exercise training on serum osteocalcin, adipocytokines and insulin resistance on obese young males. *Clinical endocrinology*. 2015;82(5):686-94.
 108. Ahn N, Kim K. Effects of 12-week exercise training on osteocalcin, high-sensitivity C-reactive protein concentrations, and insulin resistance in elderly females with osteoporosis. *Journal of physical therapy science*. 2016;28(8):2227-31.
 109. Levinger I, Scott D, Nicholson GC, Stuart AL, Duque G, McCorquodale T, et al. Uncarboxylated osteocalcin, muscle strength and indices of bone health in older women. *Bone*. 2014;64(1):8-12.
 110. Evrard S, Delanaye P, Kamel S, Cristol J-P, Cavalier E, Arnaud J, et al. Vascular calcification: from pathophysiology to biomarkers. *Clinica chimica acta*. 2015;438(1):401-14.
 111. Dou J, Li H, Ma X, Zhang M, Fang Q, Nie M, et al. Osteocalcin attenuates high fat diet-induced impairment of endothelium-dependent relaxation through Akt/eNOS-dependent pathway. *Cardiovascular Diabetology*. 2014;13(1):1-12.
 112. Kondo A, Kawakubo-Yasukochi T, Mizokami A, Chishaki S, Takeuchi H, Hirata M. Uncarboxylated osteocalcin increases serum nitric oxide levels and ameliorates hypercholesterolemia in mice fed an atherogenic diet. *Electronic Journal of Biology*. 2016;13(1):1-7.
 113. Jung CH, Lee WJ, Hwang JY, Lee MJ, Seol SM, Kim YM, et al. The preventive effect of uncarboxylated osteocalcin against free fatty acid-induced endothelial apoptosis through the activation of phosphatidylinositol 3-kinase/Akt signaling pathway. *Metabolism*. 2013;62(9):1250-7.
 114. Tacey A, Qaradakh T, Brennan-Speranza T, Hayes A, Zulli A, Levinger I. Potential role for osteocalcin in the development of atherosclerosis and blood vessel disease. *Nutrients*. 2018;10(10):1-15.
 115. Ruffenach G, Chabot S, Tanguay VF, Courboulin A, Boucherat O, Potus F, et al. Role for runt-related transcription factor 2 in proliferative and calcified vascular lesions in pulmonary arterial hypertension. *American journal of respiratory and critical care medicine*. 2016;194(10):1273-85.
 116. Millar SA, John SG, McIntyre CW, Ralevic V, Anderson SI, O'Sullivan SE. An investigation into the role of osteocalcin in human arterial smooth muscle cell calcification. *Frontiers in Endocrinology*. 2020;11(2):1-11.
 117. Liberman M, Pesaro AEP, Carmo LS, Serrano Jr CV. Vascular calcification: pathophysiology and clinical implications. *Einstein (Sao Paulo)*. 2013;11(1):376-82.
 118. Millar SA, Patel H, Anderson SI, England TJ, O'Sullivan SE. Osteocalcin, vascular calcification, and atherosclerosis: a systematic review and meta-analysis. *Frontiers in Endocrinology*. 2017;8(1):1-15.
 119. Lei Y, Sinha A, Nosoudi N, Grover A, Vyavahare N. Hydroxyapatite and calcified elastin induce osteoblast-like differentiation in rat aortic smooth muscle cells. *Experimental cell research*. 2014;323(1):198-208.
 120. Nahar-Gohad P, Gohad N, Tsai C-C, Bordia R, Vyavahare N. Rat aortic smooth muscle cells cultured on hydroxyapatite differentiate into osteoblast-like cells via BMP-2–SMAD-5 pathway. *Calcified tissue international*. 2015;96(4):359-69.
 121. Singh A, Gill G, Kaur H, Amhmed M, Jakhu H. Role of osteopontin in bone remodeling and orthodontic tooth movement: a review. *Progress in orthodontics*. 2018;19(1):1-8.
 122. Icer MA, Gezmen-Karadag M. The multiple functions and mechanisms of osteopontin. *Clinical biochemistry*. 2018;59(1):17-24.
 123. Lenton S, Grimaldo M, Roosen-Runge F, Schreiber F, Nylander T, Clegg R, et al. Effect of phosphorylation on a human-like osteopontin peptide. *Biophysical journal*. 2017;112(8):1586-96.
 124. Lok ZSY, Lyle AN. Osteopontin in vascular disease: friend or foe? *Arteriosclerosis, thrombosis, and vascular biology*. 2019;39(4):613-22.
 125. Ukkat J, Hoang-Vu C, Trojanowicz B, Rebelo A. Osteocalcin, osteopontin and RUNX2 expression in patients with arteriosclerosis. *World Academy of Sciences Journal*. 2021;3(3):1-7.
 126. Berezin A. The controversial role of osteopontin in vascular calcification: from bench to bedside. *MOJ Proteomics Bioinform*. 2017;5(4):129-30.
 127. Wolak T. Osteopontin—a multi-modal marker and mediator in atherosclerotic vascular disease. *Atherosclerosis*. 2014;236(2):327-37.
 128. Abdalrhim AD, Marroush TS, Austin EE, Gersh BJ, Solak N, Rizvi SA, et al. Plasma osteopontin levels and adverse cardiovascular outcomes in the PEACE trial. *PLoS one*. 2016;11(6):1-12.
 129. Bonetti A, Marchini M, Ortolani F. Ectopic mineralization in heart valves: new insights from in vivo and in vitro procalcific models and promising perspectives on noncalcifiable bioengineered valves. *Journal of thoracic disease*. 2019;11(5):2126-43.
 130. Tousoulis D, Siasos G, Maniatis K, Oikonomou E, Kioufis S, Zaromitidou M, et al. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease.

- International journal of cardiology. 2013;167(5):1924-8.
131. Shirakawa K, Endo J, Kataoka M, Katsumata Y, Anzai A, Moriyama H, et al. MerTK Expression and ERK Activation Are Essential for the Functional Maturation of Osteopontin-Producing Reparative Macrophages After Myocardial Infarction. *Journal of the American Heart Association*. 2020;9(18):1-25.
 132. Singh M, Dalal S, Singh K. Osteopontin: At the cross-roads of myocyte survival and myocardial function. *Life sciences*. 2014;118(1):1-6.
 133. Singh M, Foster CR, Dalal S, Singh K. Role of osteopontin in heart failure associated with aging. *Heart failure reviews*. 2010;15(5):487-94.
 134. Barrett H, O’Keeffe M, Kavanagh E, Walsh M, O’Connor EM. Is matrix Gla protein associated with vascular calcification? A systematic review. *Nutrients*. 2018;10(4):1-18.
 135. Jaminon AM, Dai L, Qureshi AR, Evenepoel P, Ripsweiden J, Söderberg M, et al. Matrix Gla protein is an independent predictor of both intimal and medial vascular calcification in chronic kidney disease. *Scientific reports*. 2020;10(1):1-9.
 136. Dahlberg S, Ede J, Schurgers L, Vermeer C, Kander T, Klarin B, et al. Desphospho-uncarboxylated matrix-Gla protein is increased postoperatively in cardiovascular risk patients. *Nutrients*. 2018;10(1):1-11.
 137. Margonato A, Gorla R, Macchi A, Buzzetti F, Franzoni I, Pedrigo MC, et al. Role of plaque calcification regulators osteoprotegerin and matrix Gla-proteins in stable angina and acute myocardial infarction. *Journal of Cardiovascular Medicine*. 2015;16(3):156-62.
 138. Wen L, Chen J, Duan L, Li S. Vitamin K-dependent proteins involved in bone and cardiovascular health. *Molecular medicine reports*. 2018;18(1):3-15.
 139. Palermo A, Tuccinardi D, D’Onofrio L, Watanabe M, Maggi D, Maurizi AR, et al. Vitamin K and osteoporosis: Myth or reality? *Metabolism*. 2017;70(1):57-71.
 140. Halder M, Petsophonsakul P, Akbulut AC, Pavlic A, Bohan F, Anderson E, et al. Vitamin K: double bonds beyond coagulation insights into differences between vitamin K1 and K2 in health and disease. *International journal of molecular sciences*. 2019;20(4):1-15.
 141. Chatron N, Hammed A, Benoît E, Lattard V. Structural insights into phyloquinone (Vitamin K1), menaquinone (MK4, MK7), and menadiolone (vitamin K3) binding to VKORC1. *Nutrients*. 2019;11(1):1-20.
 142. El Asmar MS, Naoum JJ, Arbid EJ. Vitamin K dependent proteins and the role of vitamin K2 in the modulation of vascular calcification: a review. *Oman medical journal*. 2014;29(3):172-177.
 143. Tantisattamo E, Han KH, O’Neill WC. Increased vascular calcification in patients receiving warfarin. *Arteriosclerosis, thrombosis, and vascular biology*. 2015;35(1):237-42.
 144. Hartley L, Clar C, Ghannam O, Flowers N, Stranges S, Rees K. Vitamin K for the primary prevention of cardiovascular disease. *Cochrane Database of Systematic Reviews*. 2015;9(9): CD011148:1-23.
 145. De Vilder EY, Debacker J, Vanakker OM. GGCX-associated phenotypes: an overview in search of genotype-phenotype correlations. *International journal of molecular sciences*. 2017;18(2):240-246.
 146. Lai S, Coppola B, Dimko M, Galani A, Innico G, Frassetto N, et al. Vitamin D deficiency, insulin resistance, and ventricular hypertrophy in the early stages of chronic kidney disease. *Renal failure*. 2014;36(1):58-64.
 147. Yin K, You Y, Swier Y, Tang L, Radwan MM, Pandya AN, et al. Vitamin D protects against atherosclerosis via regulation of cholesterol efflux and macrophage polarization in hypercholesterolemic swine. *Arteriosclerosis, thrombosis, and vascular biology*. 2015;35(11):2432-42.
 148. Gröber U, Reichrath J, Holick M, Kisters K. Vitamin K: an old vitamin in a new perspective. *Dermato-endocrinology*. 2014;6(1): 90-6.
 149. Schwamm RJ, Coles MP, Hill MS, Mahon MF, McMullin CL, Rajabi NA, et al. A Stable Calcium Alumanyl. *Angewandte Chemie*. 2020;132(10):3956-60.
 150. Reid IR, Birstow SM, Bolland MJ. Calcium and cardiovascular disease. *Endocrinology and metabolism*. 2017;32(3):339-49.
 151. Spence LA, Weaver CM. Calcium intake, vascular calcification, and vascular disease. *Nutrition reviews*. 2013;71(1):15-22.
 152. Reid I, Gamble G, Bolland M. Circulating calcium concentrations, vascular disease and mortality: a systematic review. *Journal of internal medicine*. 2016;279:524-40.
 153. Larsson SC, Burgess S, Michaëlsson K. Association of genetic variants related to serum calcium levels with coronary artery disease and myocardial infarction. *Jama*. 2017;318(4):371-80.
 154. Procopio M, Barale M, Bertaina S, Sigrist S, Mazzetti R, Loiacono M, et al. Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms. *Endocrine*. 2014;47(2):581-9.
 155. Toka HR, Pollak MR. The role of the calcium-sensing receptor in disorders of abnormal calcium handling and cardiovascular disease. *Current opinion in nephrology and hypertension*. 2014;23(5):494-501.
 156. Ishihara M, Asakura M, Kimura K, Nakao K, Hamada C, Hirayama A. Trial design and rationale of TY-51924 as a novel Na⁺/H⁺ exchanger inhibitor in patients with ST-elevation acute myocardial infarction undergoing percutaneous coronary intervention. *Journal of cardiology*. 2014;63(1):82-7.
 157. Mozaffari MS, Liu JY, Abebe W, Baban B. Mechanisms of load dependency of myocardial ischemia reperfusion injury. *American journal of cardiovascular disease*. 2013;3(4):180-196.

158. Ji MJ, Hong JH. A Cardioplegic Solution with an Understanding of a Cardiochannelopathy. *Antioxidants*. 2021;10(12):1878-84.
159. Berger JM, Singh P, Khirmian L, Morgan DA, Chowdhury S, Arteaga-Solis E, et al. Mediation of the acute stress response by the skeleton. *Cell metabolism*. 2019;30(5):890-902.
160. Barbarash O, Zykov M, Kashtalov V, Hryachkova O, Kokov A, Gruzdeva O, et al. Increased Serum Parathyroid Hormone, Osteocalcin and Alkaline Phosphatase Are Associated with a Long-Term Adverse Cardiovascular Outcome after Coronary Artery Bypass Graft Surgery. *Diagnostics*. 2019;9(4):143-153.
161. Chen C, Nakagawa S, An Y, Ito K, Kitaichi Y, Kusumi I. The exercise-glucocorticoid paradox: How exercise is beneficial to cognition, mood, and the brain while increasing glucocorticoid levels. *Frontiers in neuroendocrinology*. 2017;44(1):83-102.
162. Tacey A, Parker L, Garnham A, Brennan-Speranza TC, Levinger I. The effect of acute and short term glucocorticoid administration on exercise capacity and metabolism. *Journal of science and medicine in sport*. 2017;20(6):543-8.
163. Tian A, Yang C, Jin Z. Osteocalcin in acute stress response: from the perspective of cardiac diseases. *Current medical research and opinion*. 2020;36(4):545-546.
164. Magni P, Macchi C, Sirtori CR, Romanelli MMC. Osteocalcin as a potential risk biomarker for cardiovascular and metabolic diseases. *Clinical Chemistry and Laboratory Medicine (CCLM)*. 2016;54(10):1579-87.
165. Wang L, Heckmann BL, Yang X, Long H. Osteoblast autophagy in glucocorticoid-induced osteoporosis. *Journal of cellular physiology*. 2019;234(4):3207-15.
166. Nguyen MM, Anita NZ, Darwish L, Major-Orfao C, Colby-Milley J, Wong SK, et al. Serum osteocalcin is associated with subjective stress in people with depression and type 2 diabetes. *Psychoneuroendocrinology*. 2020;122(1):1-10.
167. Lipowska MM, Sadowska ET, Bauchinger U, Koteja P. Stress coping and evolution of aerobic exercise performance: corticosterone levels in voles from a selection experiment. *Journal of Experimental Biology*. 2019;222(20):1-13.
168. Patel JJ, Bourne LE, Davies BK, Arnett TR, MacRae VE, Wheeler-Jones CP, et al. Differing calcification processes in cultured vascular smooth muscle cells and osteoblasts. *Experimental cell research*. 2019;380(1):100-13.
169. Balogh E, Tóth A, Méhes G, Trencsényi G, Paragh G, Jeney V. Hypoxia Triggers Osteochondrogenic Differentiation of Vascular Smooth Muscle Cells in an HIF-1 (Hypoxia-Inducible Factor 1)-Dependent and Reactive Oxygen Species-Dependent Manner. *Arteriosclerosis, thrombosis, and vascular biology*. 2019;39(6):1088-99.
170. Liu D-M, Guo X-Z, Tong H-J, Tao B, Sun L-H, Zhao H-Y, et al. Association between osteocalcin and glucose metabolism: a meta-analysis. *Osteoporosis international*. 2015;26(12):2823-33.
171. Georgiadis GS, Argyriou C, Antoniou GA, Kantartzi K, Kriki P, Theodoridis M, et al. Upper limb vascular calcification score as a predictor of mortality in diabetic hemodialysis patients. *Journal of vascular surgery*. 2015;61(6):1529-37.
172. Ghasemalipour H, Eizadi M. The effect of aerobic training on some bone formation markers (osteocalcin, alkaline phosphatase) in asthma treated with inhaled corticosteroids. *Zahedan Journal of Research in Medical Sciences*. 2018;20(1):1-9.
173. Yardley JE. Fasting may alter blood glucose responses to high-intensity interval exercise in adults with type 1 diabetes: a randomized, acute crossover study. *Canadian Journal of Diabetes*. 2020;44(8):727-33.
174. Jiang Y, Tan S, Wang Z, Guo Z, Li Q, Wang J. Aerobic exercise training at maximal fat oxidation intensity improves body composition, glycemic control, and physical capacity in older people with type 2 diabetes. *Journal of exercise science & fitness*. 2020;18(1):7-13.
175. Bowman PR, Smith GL, Gould GW. Run for your life: can exercise be used to effectively target GLUT4 in diabetic cardiac disease? *PeerJ*. 2021;9:e11485:1-35.
176. Quindry JC, Franklin BA, Chapman M, Humphrey R, Mathis S. Benefits and risks of high-intensity interval training in patients with coronary artery disease. *The American journal of cardiology*. 2019;123(8):1370-7.
177. Gomes-Neto M, Duraes AR, Reis HFCd, Neves VR, Martinez BP, Carvalho VO. High-intensity interval training versus moderate-intensity continuous training on exercise capacity and quality of life in patients with coronary artery disease: A systematic review and meta-analysis. *European Journal of Preventive Cardiology*. 2017;24(16):1696-707.
178. Hsu JJ, Fong F, Patel R, Qiao R, Lo K, Soundia A, et al. Changes in microarchitecture of atherosclerotic calcification assessed by 18 F-NaF PET and CT after a progressive exercise regimen in hyperlipidemic mice. *Journal of Nuclear Cardiology*. 2020;28 (1): 2207–2214.
179. Dun Y, Thomas RJ, Smith JR, Medina-Inojosa JR, Squires RW, Bonikowske AR, et al. High-intensity interval training improves metabolic syndrome and body composition in outpatient cardiac rehabilitation patients with myocardial infarction. *Cardiovascular diabetology*. 2019;18(104):1-11.
180. Schulman S, Goldhaber SZ, Kearon C, Kakkar AK, Schellong S, Eriksson H, et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. *Thromb Haemost*. 2015;114(1):150-7.
181. Dhillon SK, Edwards J, Wilkie J, Bungard TJ. High-Versus Low-Dose Warfarin-Related Teratogenicity: A Case Report and Systematic Review. *Journal of Obstetrics and Gynaecology Canada*. 2018;40(10):1348-57.
182. Yoon S, Bae JS, Yoo J, Nam ES, Shin DH, Kim Y. Renal Cholesterol Embolism during Warfarin Treatment. *Journal of the Korean Neurological Association*. 2018;36(3):223-5.
183. Morishima Y, Kamisato C, Honda Y, Furugohri T, Shibano T. The effects of warfarin and edoxaban, an oral direct

- factor Xa inhibitor, on gammacarboxylated (Gla-osteocalcin) and undercarboxylated osteocalcin (uc-osteocalcin) in rats. *Thrombosis research*. 2013;131(1):59-63.
184. Abdelaziz Mohamed I, Gadeau A-P, Hasan A, Abdulrahman N, Mraiche F. Osteopontin: A promising therapeutic target in cardiac fibrosis. *Cells*. 2019;8(12):1-14.
 185. Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis. *Cellular and molecular life sciences*. 2014;71(4):549-74.
 186. Patel M, Rodriguez D, Yousefi K, John-Williams K, Mendez AJ, Goldberg RB, et al. Osteopontin and LDLR Are Upregulated in Hearts of Sudden Cardiac Death Victims With Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus. *Frontiers in Cardiovascular Medicine*. 2020;7(1):1-9.
 187. Shimodaira T, Matsuda K, Uchibori T, Sugano M, Uehara T, Honda T. Upregulation of osteopontin expression via the interaction of macrophages and fibroblasts under IL-1b stimulation. *Cytokine*. 2018;110(1):63-9.
 188. Li J, Yousefi K, Ding W, Singh J, Shehadeh LA. Osteopontin RNA aptamer can prevent and reverse pressure overload-induced heart failure. *Cardiovascular research*. 2017;113(6):633-43.
 189. Mohamed IA, Gadeau A-P, Fliegel L, Lopaschuk G, Mlih M, Abdulrahman N, et al. Na⁺/H⁺ exchanger isoform 1-induced osteopontin expression facilitates cardiomyocyte hypertrophy. *PLoS one*. 2015;10(4):1-17.
 190. Guo Y, Chen J, Qiu H. Novel Mechanisms of Exercise-Induced Cardioprotective Factors in Myocardial Infarction. *Frontiers in physiology*. 2020;10(11):199-205.
 191. Lu K, Wang L, Wang C, Yang Y, Hu D, Ding R. Effects of high-intensity interval versus continuous moderate-intensity aerobic exercise on apoptosis, oxidative stress and metabolism of the infarcted myocardium in a rat model. *Molecular medicine reports*. 2015;12(2):2374-2382.
 192. Makurina O. Functional activity of the vascular endothelium in patients with initial signs of atherosclerosis against the background of regularly dose-related exercise stress. *Research Journal of Pharmaceutical, Biological and Chemical Sciences*. 2018;9(2):1020-4.
 193. Jayo-Montoya JA, Maldonado-Martín S, Aispuru GR, Gorostegi-Anduaga I, Gallardo-Lobo R, Matajira-Chia T, et al. Low-volume high-intensity aerobic interval training is an efficient method to improve cardiorespiratory fitness after myocardial infarction: Pilot study from the interfarct project. *Journal of cardiopulmonary rehabilitation and prevention*. 2020;40(1):48-54.
 194. Aw NH, Canetti E, Suzuki K, Goh J. Monocyte subsets in atherosclerosis and modification with exercise in humans. *Antioxidants*. 2018;7(12):1-12.
 195. Nayeibi Far S, TaheriChadorneshin H. Aerobic exercise training reduces inflammatory markers involved in atherosclerosis. *Journal of Basic Research in Medical Sciences*. 2018;5(1):29-37.
 196. Santos LP, Umpierre D. Exercise, cardiovascular health, and risk factors for atherosclerosis: a narrative review on these complex relationships and caveats of literature. *Frontiers in Physiology*. 2020;11(1):1-13.
 197. Zwakenberg SR, van der Schouw YT, Vermeer C, Pasterkamp G, den Ruijter HM, Beulens JW. Matrix Gla protein, plaque stability, and cardiovascular events in patients with severe atherosclerotic disease. *Cardiology*. 2018;141(1):32-6.
 198. Bonewald L. Use it or lose it to age: A review of bone and muscle communication. *Bone*. 2019;120(1):212-8.
 199. Ke R, Zheng L, Zhao F, Xia J. Osteopontin Promotes Trophoblast Invasion in the Smooth Muscle Cell-Endothelial Co-Culture At Least Via Targeting Integrin $\alpha\beta 3$. *Cell Transplantation*. 2020;29(1):1-10.
 200. Yan Y, Jiang F, Lai Y, Wang H, Liu A, Wang C, et al. Effect of Thyrotropin on Osteopontin, Integrin $\alpha\beta 3$, and VCAM-1 in the Endothelium via Activation of Akt. *International journal of molecular sciences*. 2016;17(9):1-15.
 201. Qiu F, Liu X, Zhang Y, Wu Y, Xiao D, Shi L. Aerobic exercise enhanced endothelium-dependent vasorelaxation in mesenteric arteries in spontaneously hypertensive rats: the role of melatonin. *Hypertension Research*. 2018;41(9):718-29.
 202. Duan Z-p, Yu X-j, Li J-j, Zhao J. Pillbug extracts inhibit osteopontin-induced vascular smooth muscle cell proliferation by modulation of integrin kinase protein pathway. *Chinese Journal of Tissue Engineering Research*. 2017;21(16):25-82.
 203. Jang MA, Baek SE, Kim EJ, Park SY, Choi YW, Kim CD. Alpha-iso-cubebene attenuates VSMC proliferation induced by PDGF via inhibition of osteopontin expression. *Atherosclerosis*. 2017;263(1):131-139.
 204. Xiao L, He H, Ma L, Da M, Cheng S, Duan Y, et al. Effects of miR-29a and miR-101a expression on myocardial interstitial collagen generation after aerobic exercise in myocardial-infarcted rats. *Archives of medical research*. 2017;48(1):27-34.
 205. Moraes-Silva IC, Rodrigues B, Coelho-Junior HJ, Feriani DJ, Irigoyen M-C. Myocardial infarction and exercise training: evidence from basic science. *Exercise for Cardiovascular Disease Prevention and Treatment*. 2017; 999(1):139-53.
 206. Baghaiee B, Karimi P, Siahkouhian M, Pescatello LS. Moderate aerobic exercise training decreases middle-aged induced pathologic cardiac hypertrophy by improving Klotho expression, MAPK signaling pathway, and oxidative stress status in Wistar rats. *Iranian journal of basic medical sciences*. 2018;21(9):911-919.
 207. Li S, Gou T, Wang Q, Chen M, Chen Z, Xu M, et al. Ultrasound/Optical Dual-Modality Imaging for Evaluation of Vulnerable Atherosclerotic Plaques with Osteopontin Targeted Nanoparticles. *Macromolecular bioscience*. 2020;20(2):1-10.
 208. Sawaki D, Czibik G, Pini M, Ternacle J, Suffee N, Mercedes R, et al. Visceral adipose tissue drives cardiac aging

- through modulation of fibroblast senescence by osteopontin production. *Circulation*. 2018;138(8):809-22.
209. Mostafa DG, Satti HH, Khaleel EF, Badi RM. A high-fat diet rich in corn oil exaggerates the infarct size and memory impairment in rats with cerebral ischemia and is associated with suppressing osteopontin and Akt, and activating GS3K β , iNOS, and NF- κ B. *Journal of physiology and biochemistry*. 2020;76 (1):393-406.
 210. You T, Arsenis NC, Disanzo BL, LaMonte MJ. Effects of exercise training on chronic inflammation in obesity. *Sports Medicine*. 2013;43(4):243-56.
 211. You JS, Ji H-I, Chang KJ, Yoo MC, Yang H-I, Jeong I-K, et al. Serum osteopontin concentration is decreased by exercise-induced fat loss but is not correlated with body fat percentage in obese humans. *Molecular medicine reports*. 2013;8(2):579-84.
 212. Kochetkova EA, Ugai LG, Maistrovskaia YV, Nevzorova VA. Adipokines: a possible contribution to vascular and bone remodeling in idiopathic pulmonary arterial hypertension. *Calcified tissue international*. 2017;100(4):325-31.
 213. Saeidi A, Tayebi SM, Khosravi A, Razi O, Sellami M, Abderrahman AB, et al. Obesity, Fat Mass, Osteopontin and Exercise Training. *International Journal of Applied Exercise Physiology*. 2019;8(1):177-9.
 214. Jespersen T, Møllehave L, Thuesen B, Skaaby T, Rossing P, Toft U, et al. Uncarboxylated matrix Gla-protein: A biomarker of vitamin K status and cardiovascular risk. *Clinical biochemistry*. 2020;83(1):49-56.
 215. Wei F-F, Trenson S, Thijs L, Huang Q-F, Zhang Z-Y, Yang W-Y, et al. Desphospho-uncarboxylated matrix Gla protein is a novel circulating biomarker predicting deterioration of renal function in the general population. *Nephrology Dialysis Transplantation*. 2018;33(7):1122-8.
 216. Kränkel N, van Craenenbroeck E, Adams V. *Exercise and Vascular Function*. Textbook of Sports and Exercise Cardiology: Springer; 2020. p. 823-59.ebook.
 217. Bronas UG, Puzantian H, Hannan M. Cognitive impairment in chronic kidney disease: vascular milieu and the potential therapeutic role of exercise. *BioMed research international*. 2017;19(2): 1-10.
 218. Sangha GS, Goergen CJ, Prior SJ, Ranadive SM, Clyne AM. Preclinical techniques to investigate exercise training in vascular pathophysiology. *American Journal of Physiology-Heart and Circulatory Physiology*. 2021;320(4):H1566-H600.
 219. Zhou Y, Hellberg M, Hellmark T, Höglund P, Clyne N. Twelve months of exercise training did not halt abdominal aortic calcification in patients with CKD—a sub-study of RENEXC-a randomized controlled trial. *BMC nephrology*. 2020;21(1):1-10.
 220. Hiam D, Voisin S, Yan X, Landen S, Jacques M, Papadimitriou ID, et al. The association between bone mineral density gene variants and osteocalcin at baseline, and in response to exercise: The gene SMART study. *Bone*. 2019;123:23-7.
 221. Willems BA, Vermeer C, Reutelingsperger CP, Schurgers LJ. The realm of vitamin K dependent proteins: shifting from coagulation toward calcification. *Molecular nutrition & food research*. 2014;58(8):1620-35.
 222. Ammirati E, Moroni F, Norata GD, Magnoni M, Camici PG. Markers of inflammation associated with plaque progression and instability in patients with carotid atherosclerosis. *Mediators of inflammation*. 2015;20(15):1-15.
 223. Zhang Y-T, Tang Z-Y. Research progress of warfarin-associated vascular calcification and its possible therapy. *Journal of cardiovascular pharmacology*. 2014;63(1):76-82.
 224. Thamratnopkoon S, Susantitaphong P, Tumkosit M, Katavetin P, Tiranathanagul K, Praditpornsilpa K, et al. Correlations of plasma desphosphorylated uncarboxylated matrix Gla protein with vascular calcification and vascular stiffness in chronic kidney disease. *Nephron*. 2017;135(3):167-72.
 225. Hallajzadeh J, Ghorbanihaghjo A, Argani H, Dastmalchi S, Rashtchizadeh N. Growth arrest-specific 6 protein and matrix Gla protein in hemodialysis patients. *Iranian journal of kidney diseases*. 2015;9(3):249-255.
 226. Qiu C, Zheng H, Tao H, Yu W, Jiang X, Li A, et al. Vitamin K2 inhibits rat vascular smooth muscle cell calcification by restoring the Gas6/Axl/Akt anti-apoptotic pathway. *Molecular and cellular biochemistry*. 2017;433(1):149-59.
 227. Roumeliotis S, Dounousi E, Salmas M, Eleftheriadis T, Liakopoulos V. Vascular calcification in chronic kidney disease: The role of vitamin K-dependent matrix Gla protein. *Frontiers in medicine*. 2020;24(7):154-159.
 228. Houtman E, de Almeida RC, Tuerlings M, Suchiman E, Broekhuis D, Nelissen RG, et al. Characterization of dynamic changes in Matrix Gla Protein (MGP) gene expression as function of genetic risk alleles, osteoarthritis relevant stimuli, and the vitamin K inhibitor warfarin. *Osteoarthritis and Cartilage*. 2021 29(8): 1193-1202.
 229. Radulescu D, Stroescu A, Pricop C, Geavlete B, Negrei C, Bratu O, et al. Vitamin K influence on cardiovascular mortality in chronic hemodialysed patients. *Rev Chim (Bucharest)*. 2017;68(1):52-4.
 230. Sabrina-Wong-Peixin Haroon B-C, Tai L-HL, Lynette Teo AD, Leon Schurgers B-WT, Priyanka Khatri C-CO, Sanmay Low X-EY, et al. Treatment to reduce vascular calcification in hemodialysis patients using vitamin K (Trevasc-HDK) a study protocol for a randomized controlled trial. *Medicine*. 2020;99(36):1-8 .
 231. Kurnatowska I, Grzelak P, Masajtis-Zagajewska A, Kaczmarek M, Stefańczyk L, Vermeer C, et al. Effect of vitamin K. *Polskie Archiwum Medycyny Wewnętrznej*. 2015;125(9):631-40.
 232. Girolami A, Ferrari S, Cosi E, Santarossa C, Randi ML. Vitamin K-dependent coagulation factors that may be responsible for both bleeding and thrombosis (FII, FVII, and FIX). *Clinical and Applied Thrombosis/Hemostasis*. 2018;24(9-suppl):42S-7S.
 233. McFarlin BK, Henning AL, Venable AS. Oral Consumption of Vitamin K2 for 8 Weeks Associated With Increased Maximal Cardiac Output During Exercise. *Alternative Therapies in Health & Medicine*. 2017;23(4):26-32.
 234. Hamidi MS, Gajic-Veljanoski O, Cheung AM. Vitamin K and bone health. *Journal of clinical densitometry*.

- 2013;16(4):409-13.
235. Caluwé R, Pyfferoen L, De Boeck K, De Vriese AS. The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials. *Clinical kidney journal*. 2016;9(2):273-9.
236. Barry EL, Mott LA, Melamed ML, Rees JR, Ivanova A, Sandler RS, et al. Calcium supplementation increases blood creatinine concentration in a randomized controlled trial. *PLoS one*. 2014;9(10):1-9.
237. Anderson JJ, Kruszka B, Delaney JA, He K, Burke GL, Alonso A, et al. Calcium intake from diet and supplements and the risk of coronary artery calcification and its progression among older adults: 10-year follow-up of the Multi-Ethnic Study of Atherosclerosis (MESA). *Journal of the American Heart Association*. 2016;5(10):1-8.
238. Shankar TS, Ramadurai DK, Steinhilber K, Sommakia S, Badolia R, Krokidi AT, et al. Cardiac-specific deletion of voltage dependent anion channel 2 leads to dilated cardiomyopathy by altering calcium homeostasis. *Nature communications*. 2021;12(1):1-15.
239. Ren Z, Yang K, Zhao M, Liu W, Zhang X, Chi J, et al. Calcium-sensing receptor on neutrophil promotes myocardial apoptosis and fibrosis after acute myocardial infarction via NLRP3 inflammasome activation. *Canadian Journal of Cardiology*. 2020;36(6):893-905.
240. Xu J, Qin X, Cai X, Yang L, Xing Y, Li J, et al. Mitochondrial JNK activation triggers autophagy and apoptosis and aggravates myocardial injury following ischemia/reperfusion. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease*. 2015;1852(2):262-70.
241. Sultana RN, Sabag A, Keating SE, Johnson NA. The effect of low-volume high-intensity interval training on body composition and cardiorespiratory fitness: a systematic review and meta-analysis. *Sports Medicine*. 2019;49(11):1687-721.
242. Zhang S-S, Zhou S, Crowley-McHattan ZJ, Wang R-Y, Li J-P. A Review of the Role of Endo/Sarcoplasmic Reticulum-Mitochondria Ca^{2+} Transport in Diseases and Skeletal Muscle Function. *International Journal of Environmental Research and Public Health*. 2021;18(8):1-12.
243. Lombardi G, Ziemann E, Banfi G, Corbetta S. Physical activity-dependent regulation of parathyroid hormone and calcium-phosphorus metabolism. *International Journal of Molecular Sciences*. 2020;21(15):1-50.
244. Qin R, Murakoshi N, Xu D, Tajiri K, Feng D, Stujanna EN, et al. Exercise training reduces ventricular arrhythmias through restoring calcium handling and sympathetic tone in myocardial infarction mice. *Physiological reports*. 2019;7(4):1-14.
245. Al Dahamsheh Z, Al Rashdan K, Al Hadid A, Jaradat Rd, Al Bakheet M, Bataine ZS. The Impact of Aerobic Exercise on Female Bone Health Indicators. *Medical Archives*. 2019;73(1):35-38.
246. Elango K, Javaid A, Khetarpal BK, Ramalingam S, Kolandaivel KP, Gunasekaran K, et al. The Effects of Warfarin and Direct Oral Anticoagulants on Systemic Vascular Calcification: A Review. *Cells*. 2021;10(4):1-14.
247. Russell PS, Hong J, Windsor JA, Itkin M, Phillips ARJ. Renal lymphatics: anatomy, physiology, and clinical implications. *Frontiers in physiology*. 2019;14(10):1-18.
248. Osman A, Clayton R. Adrenocortical hormones. *Anaesthesia & Intensive Care Medicine*. 2017;18(10):519-21.
249. Moinuddin Z, Dhanda R. Anatomy of the kidney and ureter. *Anaesthesia & Intensive Care Medicine*. 2015;16(6):247-52.
250. Panchal HB, Zheng S, Devani K, White CJ, Leinaar EF, Mukherjee D, et al. Impact of Chronic Kidney Disease on Revascularization and Outcomes in Patients with ST-Elevation Myocardial Infarction. *The American Journal of Cardiology*. 2021;150(1):15-23.
251. Wang C, Pei Y-Y, Ma Y-H, Ma X-L, Liu Z-W, Zhu J-H, et al. Risk factors for acute kidney injury in patients with acute myocardial infarction. *Chinese medical journal*. 2019;132(14):1660-65.
252. Blicher TM, Hommel K, Olesen JB, Torp-Pedersen C, Madsen M, Kamper A-L. Less use of standard guideline-based treatment of myocardial infarction in patients with chronic kidney disease: a Danish nation-wide cohort study. *European heart journal*. 2013;34(37):2916-23.
253. Ohno K, Kuno A, Murase H, Muratsubaki S, Miki T, Tanno M, et al. Diabetes increases the susceptibility to acute kidney injury after myocardial infarction through augmented activation of renal Toll-like receptors in rats. *American Journal of Physiology-Heart and Circulatory Physiology*. 2017;313(6):H1130-H42.
254. Paulus P, Rupprecht K, Baer P, Obermüller N, Penzkofer D, Reissig C, et al. The early activation of toll-like receptor (TLR)-3 initiates kidney injury after ischemia and reperfusion. *PLoS One*. 2014;9(4):1-12.
255. Verzola D, Cappuccino L, D'amato E, Villaggio B, Gianiorio F, Mij M, et al. Enhanced glomerular Toll-like receptor 4 expression and signaling in patients with type 2 diabetic nephropathy and microalbuminuria. *Kidney international*. 2014;86(6):1229-43.
256. Cho E, Kim M, Ko YS, Lee HY, Song M, Kim MG, et al. Role of inflammation in the pathogenesis of cardiorenal syndrome in a rat myocardial infarction model. *Nephrology Dialysis Transplantation*. 2013;28(11):2766-78.
257. Liu F-Y, Fan D, Yang Z, Tang N, Guo Z, Ma S-Q, et al. TLR9 is essential for HMGB1-mediated post-myocardial infarction tissue repair through affecting apoptosis, cardiac healing, and angiogenesis. *Cell death & disease*. 2019;10(7):1-16.
258. Helseth R, Solheim S, Arnesen H, Seljeflot I, Opstad TB. The time course of markers of neutrophil extracellular traps in patients undergoing revascularisation for acute myocardial infarction or stable angina pectoris. *Mediators of inflammation*. 2016;20(6):1-9.

259. Tsuji N, Tsuji T, Ohashi N, Kato A, Fujigaki Y, Yasuda H. Role of mitochondrial DNA in septic AKI via toll-like receptor 9. *Journal of the American Society of Nephrology*. 2016;27(7):2009-20.
260. Pundir C, Yadav S, Kumar A. Creatinine sensors. *TrAC Trends in Analytical Chemistry*. 2013;50(1):42-52.
261. Cánovas R, Cuartero M, Crespo GA. Modern creatinine (Bio) sensing: Challenges of point-of-care platforms. *Bio-sensors and Bioelectronics*. 2019;130(1):110-24.
262. Lin Y-L, Chen S-Y, Lai Y-H, Wang C-H, Kuo C-H, Liou H-H, et al. Serum creatinine to cystatin C ratio predicts skeletal muscle mass and strength in patients with non-dialysis chronic kidney disease. *Clinical Nutrition*. 2020;39(8):2435-41.
263. Levey AS, Inker LA, Coresh J. Chronic kidney disease in older people. *Jama*. 2015;314(6):557-8.
264. Tseng C-C, Yang R-J, Ju W-J, Fu L-M. Microfluidic paper-based platform for whole blood creatinine detection. *Chemical engineering journal*. 2018;348(1):117-24.
265. Schneider C, Coll B, Jick SS, Meier CR. Doubling of serum creatinine and the risk of cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes mellitus: a cohort study. *Clinical epidemiology*. 2016;8(1):177-184.
266. Liu S, Niu J, Wu S, Xin Z, Zhao Z, Xu M, et al. Urinary albumin-to-creatinine ratio levels are associated with subclinical atherosclerosis and predict CVD events and all-cause deaths: a prospective analysis. *BMJ open*. 2021;11(3):1-10.
267. Olechnowicz-Tietz S, Gluba A, Paradowska A, Banach M, Rysz J. The risk of atherosclerosis in patients with chronic kidney disease. *International urology and nephrology*. 2013;45(6):1605-12.
268. Varbo A, Benn M, Tybjaerg-Hansen A, Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. *Journal of the American College of Cardiology*. 2013;61(4):427-36.
269. Manoeuvrier G, Bach-Ngohou K, Batard E, Masson D, Treweek D. Diagnostic performance of serum blood urea nitrogen to creatinine ratio for distinguishing prerenal from intrinsic acute kidney injury in the emergency department. *BMC nephrology*. 2017;18(1):1-7.
270. Arihan O, Wernly B, Lichtenauer M, Franz M, Kabisch B, Muessig J, et al. Blood Urea Nitrogen (BUN) is independently associated with mortality in critically ill patients admitted to ICU. *PLoS One*. 2018;13(1):1-10.
271. Lan Q, Zheng L, Zhou X, Wu H, Buys N, Liu Z, et al. The Value of Blood Urea Nitrogen in the Prediction of Risks of Cardiovascular Disease in an Older Population. *Frontiers in Cardiovascular Medicine*. 2021;8(1):1-8.
272. Liu J, Sun L-L, Wang J, Ji G. Blood urea nitrogen in the prediction of in-hospital mortality of patients with acute aortic dissection. *Cardiology journal*. 2018;25(3):371-6.
273. Gary T, Pichler M, Schilcher G, Hafner F, Hackl G, Rief P, et al. Elevated blood urea nitrogen is associated with critical limb ischemia in peripheral arterial disease patients. *Medicine*. 2015;94(24):948-52.
274. Amini N, Sadeghi A, Hemmati Afif A. The Effect of Eight-week Caffeine Supplementation and High-Intensity Interval Training on the Serum Urea and Creatinine Levels and Morphological Changes of Glomerular Unit in Diabetic Rats. *Journal of Kerman University of Medical Sciences*. 2020;27(6):520-36.
275. Grubb A. Cystatin C is indispensable for evaluation of kidney disease. *EJIFCC*. 2017;28(4):268-276.
276. Nakhjavan-Shahraki B, Yousefifard M, Ataei N, Baikpour M, Ataei F, Bazargani B, et al. Accuracy of cystatin C in prediction of acute kidney injury in children; serum or urine levels: which one works better? A systematic review and meta-analysis. *BMC nephrology*. 2017;18(1):1-13.
277. Wu H, Du Q, Dai Q, Ge J, Cheng X. Cysteine protease cathepsins in atherosclerotic cardiovascular diseases. *Journal of atherosclerosis and thrombosis*. 2017;24(1):1-13.
278. Van Der Laan SW, Fall T, Soumaré A, Teumer A, Sedaghat S, Baumert J, et al. Cystatin C and cardiovascular disease: a Mendelian randomization study. *Journal of the American College of Cardiology*. 2016;68(9):934-45.
279. Kaufman DP, Basit H, Knohl SJ. Physiology, glomerular filtration rate (GFR). 2018;16(1): 1-8.
280. Mangan C, Stott MC, Dhanda R. Renal physiology: blood flow, glomerular filtration and plasma clearance. *Anaesthesia & Intensive Care Medicine*. 2018;19(5):254-7.
281. Navar LG. Intrarenal renin-angiotensin system in regulation of glomerular function. *Current opinion in nephrology and hypertension*. 2014;23(1):1-15.
282. Kanbay M, Ertuglu LA, Afsar B, Ozdogan E, Kucuksumer ZS, Ortiz A, et al. Renal hyperfiltration defined by high estimated glomerular filtration rate: a risk factor for cardiovascular disease and mortality. *Diabetes, Obesity and Metabolism*. 2019;21(11):2368-83.
283. Chalikias G, Serif L, Kikas P, Thomaidis A, Stakos D, Makrygiannis D, et al. Long-term impact of acute kidney injury on prognosis in patients with acute myocardial infarction. *International journal of cardiology*. 2019;283(1):48-54.
284. Najafi M. Serum creatinine role in predicting outcome after cardiac surgery beyond acute kidney injury. *World journal of cardiology*. 2014;6(9):1006-2021.
285. Margolis G, Gal-Oz A, Khoury S, Keren G, Shacham Y. Relation of subclinical serum creatinine elevation to adverse in-hospital outcomes among myocardial infarction patients. *European Heart Journal: Acute Cardiovascular Care*. 2018;7(8):732-8.
286. Losito A, Nunzi E, Pittavini L, Zampi I, Zampi E. Cardiovascular morbidity and long term mortality associated with in hospital small increases of serum creatinine. *Journal of nephrology*. 2018;31(1):71-7.
287. Kayacan Y, Kaya Y, Makaracı Y. Excretion of creatinine, uric acid and micropoteins by general body massage applied after exercise. *European Journal of Physical Education and Sport Science*. 2017;3(6):36-47.

288. Martínez R, Kapravelou G, López-Chaves C, Cáceres E, Coll-Risco I, Sánchez-González C, et al. Aerobic interval exercise improves renal functionality and affects mineral metabolism in obese Zucker rats. *American Journal of Physiology-Renal Physiology*. 2019;316(1):F90-F100.
289. Yoshida N, Miyake T, Yamamoto S, Furukawa S, Senba H, Kanzaki S, et al. The serum creatinine level might be associated with the onset of impaired fasting glucose: a community-based longitudinal cohort health checkup study. *Internal Medicine*. 2019;58(4):505-10.
290. Golla A, Goli R, Nagalla V, Kiran B, Raju D, Uppin M. Warfarin-related nephropathy. *Indian journal of nephrology*. 2018;28(5):378-81.
291. Lim AK. Haematuria and acute kidney injury associated with warfarin anticoagulation. *General Med*. 2013;1(105):1-6.
292. Horiuchi Y, Aoki J, Tanabe K, Nakao K, Ozaki Y, Kimura K, et al. A high level of blood urea nitrogen is a significant predictor for in-hospital mortality in patients with acute myocardial infarction. *International heart journal*. 2018;59(2):263-71.
293. Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Higher blood urea nitrogen is associated with increased risk of incident diabetes mellitus. *Kidney international*. 2018;93(3):741-52.
294. Takaya Y, Yoshihara F, Yokoyama H, Kanzaki H, Kitakaze M, Goto Y, et al. Risk stratification of acute kidney injury using the blood urea nitrogen/creatinine ratio in patients with acute decompensated heart failure. *Circulation Journal*. 2015;79(7):1520-5.
295. Sokal P, Jastrzębski Z, Jaskulska E, Sokal K, Jastrzębska M, Radziński Ł, et al. Differences in blood urea and creatinine concentrations in earthed and unearthed subjects during cycling exercise and recovery. *Evidence-based complementary and alternative medicine*. 2013;11(1):1-6.
296. Zhang Y, Qi L, Xu L, Sun X, Liu W, Zhou S, et al. Effects of exercise modalities on central hemodynamics, arterial stiffness and cardiac function in cardiovascular disease: Systematic review and meta-analysis of randomized controlled trials. *PLoS One*. 2018;13(7):1-28.
297. Ito S. High-intensity interval training for health benefits and care of cardiac diseases-the key to an efficient exercise protocol. *World Journal of Cardiology*. 2019;11(7):171-188.
298. Smilowitz NR, Gupta N, Guo Y, Mauricio R, Bangalore S. Management and outcomes of acute myocardial infarction in patients with chronic kidney disease. *International journal of cardiology*. 2017;227(1):1-7.
299. Ichihara N, Ishigami T, Umemura S. Effect of impaired renal function on the maintenance dose of warfarin in Japanese patients. *Journal of cardiology*. 2015;65(3):178-84.
300. Scicchitano P, Tucci M, Bellino MC, Cortese F, Cecere A, De Palo M, et al. The impairment in kidney function in the oral anticoagulation era. A pathophysiological insight. *Cardiovascular Drugs and Therapy*. 2021;35(3):505-519.
301. Peng H, Wang Q, Lou T, Qin J, Jung S, Shetty V, et al. Myokine mediated muscle-kidney crosstalk suppresses metabolic reprogramming and fibrosis in damaged kidneys. *Nature communications*. 2017;8(1):1-15.
302. Benoit SW, Ciccia EA, Devarajan P. Cystatin C as a biomarker of chronic kidney disease: latest developments. *Expert Review of Molecular Diagnostics*. 2020;20(10):1019-26.
303. Kim T-H, Kim H, Kim I-C. The potential of cystatin-C to evaluate the prognosis of acute heart failure: a comparative study. *Acute cardiac care*. 2015;17(4):72-6.
304. Malik J. Heart disease in chronic kidney disease—Review of the mechanisms and the role of dialysis access. *The journal of vascular access*. 2018;19(1):3-11.
305. Luis-Lima S, Escamilla-Cabrera B, Negrín-Mena N, Estupiñán S, Delgado-Mallén P, Marrero-Miranda D, et al. Chronic kidney disease staging with cystatin C or creatinine-based formulas: flipping the coin. *Nephrology Dialysis Transplantation*. 2019;34(2):287-94.
306. Opatowsky AR, Carazo M, Singh MN, Dimopoulos K, Cardona-Estrada DA, Elantably A, et al. Creatinine versus cystatin C to estimate glomerular filtration rate in adults with congenital heart disease: Results of the Boston Adult Congenital Heart Disease Biobank. *American heart journal*. 2019;214(1):142-55.
307. Huerta A, López B, Ravassa S, San José G, Querejeta R, Beloqui Ó, et al. Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients: potential role of altered collagen metabolism. *Journal of hypertension*. 2016;34(1):130-8.
308. Král A, Kovárník T, Vanickova Z, Skalická H, Horák J, Bayerová K, et al. Cystatin C is associated with the extent and characteristics of coronary atherosclerosis in patients with preserved renal function. *Folia biologica*. 2016;62(6):1-10.
309. Pérez FJR, Bonafonte LF, Guerediaga DI, Belaza MPO, Peyron PU. Effect of an individualised physical exercise program on lipid profile in sedentary patients with cardiovascular risk factors. *Clínica e Investigación en Arteriosclerosis (English Edition)*. 2017;29(5):201-8.
310. Volaklis K, Thorand B, Peters A, Halle M, Margot H, Amann U, et al. Muscular Strength is Independently Associated with Cystatin C: The KORA-Age Study. *International journal of sports medicine*. 2018;39(03):225-31.
311. Rey DR, Sanchez-Lastra MA, Pérez CA, editors. Impact of aquatic exercise on persons with kidney disease: a systematic review and meta-analysis. *Camp*; 2020;37(5):339-347.
312. Srilakshmi P, Reddy YR, Rambabu K, Rao SV. Cystatin C, oxidative stress and body fat distribution in the middle aged individuals with coronary artery disease. *International Journal of Clinical Biochemistry and Research*. 2020;5(4):622-6.

313. Beetham KS, Howden EJ, Isbel NM, Coombes JS. Agreement between cystatin-C and creatinine based eGFR estimates after a 12-month exercise intervention in patients with chronic kidney disease. *BMC nephrology*. 2018;19(1):1-11.
314. Sarmadiyan M, Khorshidi D. Effect of combined endurance and strength training on cystatin C, high-sensitivity C-reactive protein level and cardiovascular risk factors in sedentary postmenopausal women. *Journal of Gorgan University of Medical Sciences*. 2016;18(3):45-51.
315. Duman A, Ayhan A, Dagli B, Kapci M, Avcil M, Ozdemir F. Analysis of patients admitted to the emergency service for warfarin complication and determination of their levels of knowledge and requirements of knowledge about warfarin use. *Journal of Experimental and Clinical Medicine*. 2017;34(4):247-50.
316. Chen H-Y, Ou S-H, Huang C-W, Lee P-T, Chou K-J, Lin P-C, et al. Efficacy and Safety of Direct Oral Anticoagulants vs Warfarin in Patients with Chronic Kidney Disease and Dialysis Patients: A Systematic Review and Meta-Analysis. *Clinical Drug Investigation*. 2021;41(1): 341–351.
317. Ishii H, Hirai K, Yanai K, Kitano T, Shindo M, Miyazawa H, et al. Warfarin-related nephropathy with acute kidney injury in a patient with immunoglobulin A nephropathy. *CEN case reports*. 2018;7(2):198-203.
318. Hu C, Li D, Yin W, Zuo X. Evaluation of cystatin C-derived glomerular filtration rate equations in Chinese population. *Scandinavian journal of clinical and laboratory investigation*. 2019;79(8):629-34.
319. Gordienko A, Lukichev B, Sotnikov A, Nosovich D, Cherticheva A, Epifanov SY, et al. Glomerular filtration rate seasonal variations in men under 60 years old within acute and subacute period of myocardial infarction. *Nephrology (Saint-Petersburg)*. 2021;25(1):70-5.
320. Carrero JJ, Hecking M, Chesnaye NC, Jager KJ. Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. *Nature Reviews Nephrology*. 2018;14(3):151-64.
321. Poulidakos D, Ross L, Recio-Mayoral A, Cole D, Andoh J, Chitalia N, et al. Left ventricular hypertrophy and endothelial dysfunction in chronic kidney disease. *European Heart Journal–Cardiovascular Imaging*. 2014;15(1):56-61.
322. Valdivielso JM, Rodríguez-Puyol D, Pascual J, Barrios C, Bermúdez-López M, Sánchez-Niño MD, et al. Atherosclerosis in chronic kidney disease: more, less, or just different? *Arteriosclerosis, thrombosis, and vascular biology*. 2019;39(10):1938-66.
323. Korolczuk A, Dudka J. Increased risk of cardiovascular complications in chronic kidney disease: a possible role of leptin. *Current pharmaceutical design*. 2014;20(4):666-74.
324. Duni A, Liakopoulos V, Rapsomanikis K-P, Dounousi E. Chronic kidney disease and disproportionately increased cardiovascular damage: does oxidative stress explain the burden? *Oxidative medicine and cellular longevity*. 2017;17(1):1-16.
325. Martínez-Milla J, García MC, Urquía MT, Castillo ML, Arbiol AD, Monteagudo ALR, et al. Blockade of Renin–Angiotensin–Aldosterone system in elderly patients with heart failure and chronic kidney disease: results of a single-center, observational cohort study. *Drugs & aging*. 2019;36(12):1123-31.
326. Chetot T, Taufana S, Benoit E, Lattard V. Vitamin K antagonist rodenticides display different teratogenic activity. *Reproductive Toxicology*. 2020;93(1):131-6.
327. Wheeler D, Giugliano R, Rangaswami J. Anticoagulation-related nephropathy. *Journal of Thrombosis and Haemostasis*. 2016;14(3):461-7.
328. Medeiros WM, de Luca FA, de Figueredo Júnior AR, Mendes FA, Gun C. Heart rate recovery improvement in patients following acute myocardial infarction: exercise training, β -blocker therapy or both. *Clinical physiology and functional imaging*. 2018;38(3):351-9.
329. Leite AB, Lima HN, de Oliveira Flores C, Oliveira CA, Cunha LEC, Neves JL, et al. High-intensity interval training is more effective than continuous training to reduce inflammation markers in female rats with cisplatin nephrotoxicity. *Life Sciences*. 2021;266(1):1-31.
330. Calvo-Lobo C, Neyra-Bohorquez PP, Seco-Calvo J. Aerobic exercise effects in renal function and quality of life of patients with advanced chronic kidney disease. *Revista da Associação Médica Brasileira*. 2019;65(1):657-62.
331. Capoor MN, Stonemetz JL, Baird JC, Ahmed FS, Awan A, Birkenmaier C, et al. Prothrombin time and activated partial thromboplastin time testing: a comparative effectiveness study in a million-patient sample. *PLoS One*. 2015;10(8):1-13.
332. Levy JH, Szlam F, Wolberg AS, Winkler A. Clinical use of the activated partial thromboplastin time and prothrombin time for screening: a review of the literature and current guidelines for testing. *Clinics in laboratory medicine*. 2014;34(3):453-77.
333. Barcellona D, Fenu L, Marongiu F. Point-of-care testing INR: an overview. *Clinical Chemistry and Laboratory Medicine (CCLM)*. 2017;55(6):800-5.
334. Kremers RM, Zuily S, Kelchtermans H, Peters TC, Bloemen S, Regnault V, et al. Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin. *Blood advances*. 2018;2(11):1315-24.
335. Kakisaka K, Suzuki Y, Kataoka K, Okada Y, Miyamoto Y, Kuroda H, et al. Predictive formula of coma onset and prothrombin time to distinguish patients who recover from acute liver injury. *Journal of gastroenterology and hepatology*. 2018;33(1):277-82.
336. Omer IAM. Estimation of prothrombin time, activated partial thromboplastin time and thrombocytes among Sudanese patients with diabetes. *GSC Biological and Pharmaceutical Sciences*. 2020;10(1):034-8.
337. Wen Tan C, Cheen MHH, Wong WH, Wu IQ, Chua BLW, Ahamedulla SH, et al. Elevated activated partial throm-

- boplastin time-based clot waveform analysis markers have strong positive association with acute venous thromboembolism. *Biochemia medica*. 2019;29(2):385-93.
338. Roshal M, Gil MR. Activated partial thromboplastin time. *Transfusion Medicine and Hemostasis: Elsevier* (ISBN: 978-0-12-813726-0); 2019. p. 779-81.
 339. Crowe EP, Goel R, Ness PM. Prothrombin and Partial Thromboplastin Time. *Trauma Induced Coagulopathy: Springer* (ISBN: 978-3-030-53605-3); 2021. p. 265-70.
 340. Rudasill SE, Liu J, Kamath AF. Revisiting the international normalized ratio (INR) threshold for complications in primary total knee arthroplasty: an analysis of 21,239 cases. *JBJS*. 2019;101(6):514-22.
 341. Schwebach AA, Waybright RA, Johnson TJ. Fixed-dose four-factor prothrombin complex concentrate for vitamin K antagonist reversal: does one dose fit all? *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*. 2019;39(5):599-608.
 342. Ranucci M, Baryshnikova E, Cotza M, Carboni G, Isgrò G, Carlucci C, et al. Coagulation monitoring in postcardiotomy ECMO: conventional tests, point-of-care, or both? *Minerva anesthesiologica*. 2016;82(8):858-66.
 343. Ali NMA, Gameel FEMH, Elsayid M, Babker AAAAA. Alterations in D-Dimer, Prothrombin time and activated partial thromboplastin time as thrombogenesis activity markers in patients with acute myocardial infarction. *Open Journal of Blood Diseases*. 2016;6(1):1-5.
 344. Caruso G. Public health and safety: The social determinants of health and criminal behavior. Gregg D Caruso. (SSRN: 3054747). 2017. 1-38.
 345. Khan HA, Alhomida AS, Al Rammah TY, Sobki SH, Ola MS, Khan AA. Alterations in prothrombin time and activated partial thromboplastin time in patients with acute myocardial infarction. *International journal of clinical and experimental medicine*. 2013;6(4):294-297.
 346. Edres MAMA, Babiker NE. Estimation of Fibrinogen Level among Sudanese Patients with Myocardial Infarction. *Journal of Drug Delivery and Therapeutics*. 2019;9(6-s):21-7.
 347. Walborn A, Williams M, Fareed J, Hoppensteadt D. International normalized ratio relevance to the observed coagulation abnormalities in warfarin treatment and disseminated intravascular coagulation. *Clinical and Applied Thrombosis/Hemostasis*. 2018;24(7):1033-41.
 348. Knauff F, Chaknos CM, Berns JS, Perazella MA. Dabigatran and kidney disease: a bad combination. *Clinical Journal of the American Society of Nephrology*. 2013;8(9):1591-7.
 349. Pu J, Ding S, Ge H, Han Y, Guo J, Lin R, et al. Efficacy and safety of a pharmaco-invasive strategy with half-dose alteplase versus primary angioplasty in ST-segment-elevation myocardial infarction: EARLY-MYO Trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute ST-Segment-Elevation Myocardial Infarction). *Circulation*. 2017;136(16):1462-73.
 350. Kawai M, Harada M, Motoike Y, Koshikawa M, Ichikawa T, Watanabe E, et al. Impact of serum albumin levels on supratherapeutic PT-INR control and bleeding risk in atrial fibrillation patients on warfarin: a prospective cohort study. *IJC Heart & Vascular*. 2019;22(1):111-6.
 351. Mega JL, Simon T. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. *The Lancet*. 2015;386(9990):281-91.
 352. Abd Elwahaab HA, Rahmy A, Hagag A, Fares HM, Fouad SA. Effect of Aerobic exercises on Blood coagulation and Fibrinolysis factors in Elderly Hypertensive patients. *J Adv Pharm Edu Res*. 2019;9(1):44-8.
 353. Ohkura N, Oishi K, Atsumi G-i. Blood coagulation and metabolic profiles in middle-aged male and female ob/ob mice. *Blood Coagulation & Fibrinolysis*. 2015;26(5):522-6.
 354. Dallak M, Bin-Jaliah I, Sakr HF, Al-Ani B, Haidara MA. Swim exercise inhibits hemostatic abnormalities in a rat model of obesity and insulin resistance. *Archives of physiology and biochemistry*. 2019;125(1):79-84.
 355. Posthuma JJ, van der Meijden PE, ten Cate H, Spronk HM. Short-and Long-term exercise induced alterations in haemostasis: a review of the literature. *Blood reviews*. 2015;29(3):171-8.
 356. Amini A, Sobhani V, Mohammadi MT, Shirvani H. Acute effects of aerobic, resistance and concurrent exercises, and maximal shuttle run test on coagulation and fibrinolytic activity in healthy young non-athletes. *The Journal of sports medicine and physical fitness*. 2017;57(5):633-42.
 357. Lamprecht M, Moussalli H, Ledinski G, Leschnik B, Schlagenhaut A, Koestenberger M, et al. Effects of a single bout of walking exercise on blood coagulation parameters in obese women. *Journal of applied physiology*. 2013;115(1):57-63.
 358. Borham MR. Effect of aerobic exercise training in patients with ischemic heart disease under anticoagulant drugs. Master's, Physical Therapy, Department of Physical Therapy for Cardiopulmonary and Geriatrics Disorders, Cairo University, 2013.
 359. Costa EC, Hay JL, Kehler DS, Boreskie KF, Arora RC, Umpierre D, et al. Effects of high-intensity interval training versus moderate-intensity continuous training on blood pressure in adults with pre-to established hypertension: a systematic review and meta-analysis of randomized trials. *Sports Medicine*. 2018;48(9):2127-42.
 360. Schmidt DE, Holmström M, Majeed A, Näslin D, Wallén H, Ågren A. Detection of elevated INR by thromboelastometry and thromboelastography in warfarin treated patients and healthy controls. *Thrombosis research*. 2015;135(5):1007-11.
 361. Nelson WW, Wang L, Baser O, Damaraju CV, Schein JR. Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation. *International journal of clinical pharmacy*. 2015;37(1):53-9.

362. Albertsen IE, Rasmussen LH, Overvad TF, Graungaard T, Larsen TB, Lip GY. Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysis. *Stroke*. 2013;44(5):1329-36.
363. Kilic L, Yildiz I, Sen FK, Erdem MG, Serilmez M, Keskin S, et al. D-dimer and international normalized ratio (INR) are correlated with tumor markers and disease stage in colorectal cancer patients. *Cancer Biomarkers*. 2015;15(4):405-11.
364. Loforte A, Fiorentino M, Gliozzi G, Mariani C, Folesani G, Suarez SM, et al., editors. Heart transplant and hepato-renal dysfunction: the model of end-stage liver disease excluding international normalized ratio as a predictor of postoperative outcomes. *Transplantation proceedings*; 2019;5(9): 2962-2966.
365. Barnes GD, Kong X, Cole D, Haymart B, Kline-Rogers E, Almany S, et al. Extended International Normalized Ratio testing intervals for warfarin-treated patients. *Journal of Thrombosis and Haemostasis*. 2018;16(7):1307-12.
366. Gashi AI, Zivkovic V, Gjorgoski I, Gontarev S, Azemi A. Original Article Regular physical activity may influence stress hormone cortisol in Wistar rats. *Journal of Physical Education and Sport*. 2020;20(1):138-141.
367. Abbasi T, Banaeifar A, Arshadi S, Kazemzadeh Y. Evaluation of the Interactive Effect of Warfarin Administration with Continuous and Interval Training on Levels of Cardiac MGP Protein and Renal Function Indexes in Rats of Myocardial Infarction Model: An Experimental Study. *JRUMS*. 2022; 21(2): 165-186. [Farsi]
368. Abbasi T, Banaeifar A, Arshadi S, Kazemzadeh Y. The Effect of Continuous and Interval Endurance Training on the Expression of OCN, OPN, MGP Genes in Heart Tissue, Renal Function Indices, Coagulation in Warfarin-treated Myocardial Infarction Rats. Ph.D. Thesis: Islamic Azad University, South Tehran Branch. Faculty of Physical Education and Exercise Sciences. 2022. [Farsi]
369. Abbasi T, Banaeifar A, Arshadi S, Kazemzadeh Y. The effect of eight weeks of continuous and interval training with warfarin supplementation on expression of cardiac osteopontin gene and coagulation indices in male Sprague-Dawley rats with myocardial infarction. *Journal of Applied Health Studies in Sport Physiology*. 2021; 8(2): 70-82. [Farsi]
370. Abbasi T, Banaeifar A, Arshadi S, Kazemzadeh Y. Evaluation of the Effect of Warfarin Consumption with Continuous and Interval Training on The Expression of Cardiac Osteocalcin, Vitamin K2 (MK-4) and Serum Calcium in a Model Of Rats With Myocardial Infarction. *Medical Journal of Mashhad University of Medical Sciences*. 2022; 65(2): 712-729. [Farsi]